Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 7/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886987 | 0.91 | MAPK8 (0.41) | SMYD3MAPK8LMNASMN1; SMN2RAB9A | |
| SCHEMBL5886797 | 0.90 | MAPK8 (0.47) | SMYD3MAPK8LMNASMN1; SMN2RAB9A | |
| SCHEMBL5886914 | 0.89 | RAB9A (0.43) | SMYD3MAPK8LMNASMN1; SMN2RAB9A | |
| SCHEMBL5886859 | 0.87 | MAPK14 (0.43) | SMYD3MAPK8LMNASMN1; SMN2RAB9A | |
| SCHEMBL5886879 | 0.87 | LMNA (0.48) | SMYD3MAPK8LMNASMN1; SMN2RAB9A | |
| SCHEMBL5887490 | 0.87 | MAPK8 (0.40) | SMYD3MAPK8LMNASMN1; SMN2RAB9A | |
| SCHEMBL5887074 | 0.86 | MAPK14 (0.49) | SMN1; SMN2RAB9ATTKNPC1KMT2A | |
| SCHEMBL5887431 | 0.86 | MMP13 (0.41) | LMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL5886851 | 0.85 | SMN1; SMN2 (0.45) | SMYD3MAPK8LMNASMN1; SMN2MAPT | |
| SCHEMBL5887279 | 0.84 | MLYCD (0.35) | MAPK8LMNARAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | SMYD3 2663/4885MAPK8 770/4885LMNA 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.